CPHI
China Pharma Holdings, Inc.
Price Chart
Latest Quote
$0.77
-0.07 (-8.19%)
Current Price
| Previous Close | $0.84 |
| Open | $0.86 |
| Day High | $0.86 |
| Day Low | $0.74 |
| Volume | 33,311 |
Stock Information
| Shares Outstanding | 40.52M |
| Total Debt | $3.56M |
| Cash Equivalents | $168K |
| Revenue | $3.99M |
| Net Income | $-3.55M |
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Market Cap | $31.25M |
| EPS (TTM) | $-0.54 |
| Exchange | ASE |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $34.64M |
| Sales | $3.99M |
| Income | $-3.55M |
| Book/sh | $1.47 |
| Cash/sh | $0.00 |
| Employees | 215 |
Financial Ratios
| Quick Ratio | 0.06 |
| Current Ratio | 0.28 |
| Debt/Eq | 9.61 |
Returns & Margins
| ROA | -7.26% |
| ROE | -16.12% |
| Gross Margin | 7.26% |
| Operating Margin | -113.60% |
| Profit Margin | -88.82% |
Ownership
| Insider Ownership | 98.02% |
| Institutional Ownership | 0.06% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| PEG | 0.16 |
| P/S | 7.83 |
| P/B | 0.53 |
Analyst Data
| Recommendation | none |
Technical Indicators
| SMA20 | $0.77 |
| SMA50 | $0.71 |
| SMA200 | $1.16 |
| RSI | 48.39 |
| ATR | 0.0921 |
| Shares Float | 37.84M |
| Short Float | 0.21% |
| Short Ratio | 0.08 |
| Rel Volume | 0.72 |
Performance History
| Week | +0.00% |
| Month | +6.94% |
| Quarter | +40.00% |
| 6 Months | -46.53% |
| YTD | -36.36% |
| Year | -57.92% |
| 3 Years | -96.05% |
| 5 Years | -99.78% |
| 10 Years | -99.38% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-18 | $0.77 | 33,400 |
| 2026-06-17 | $0.84 | 36,800 |
| 2026-06-16 | $0.78 | 35,700 |
| 2026-06-15 | $0.76 | 59,300 |
| 2026-06-12 | $0.71 | 25,000 |
| 2026-06-11 | $0.77 | 48,800 |
| 2026-06-10 | $0.77 | 57,200 |
| 2026-06-09 | $0.72 | 167,900 |
| 2026-06-08 | $0.71 | 27,200 |
| 2026-06-05 | $0.72 | 76,900 |
| 2026-06-04 | $0.82 | 32,000 |
| 2026-06-03 | $0.88 | 45,900 |
| 2026-06-02 | $0.86 | 36,100 |
| 2026-06-01 | $0.77 | 44,100 |
| 2026-05-29 | $0.79 | 34,000 |
| 2026-05-28 | $0.76 | 23,100 |
| 2026-05-27 | $0.75 | 43,900 |
| 2026-05-26 | $0.76 | 32,300 |
| 2026-05-22 | $0.76 | 32,600 |
| 2026-05-21 | $0.76 | 38,900 |
| 2026-05-20 | $0.71 | 59,200 |
| 2026-05-19 | $0.72 | 109,700 |
About China Pharma Holdings, Inc.
China Pharma Holdings, Inc. develops, manufactures, and markets pharmaceutical products for human use in the People's Republic of China. The company provides products in the form of dry powder injectables, liquid injectables, tablets, capsules, and cephalosporin oral solutions. Its products include Cerebroprotein Hydroloysate injection to treat memory decline and attention deficit; Gastrodin injection for tiredness, loss of concentration, poor sleep, and traumatic syndromes of the brain; Propylgallate injection to treat cerebral thrombosis, coronary heart disease, and after surgery complications; Ozagrel Sodium to treat acute thrombotic cerebral infarction and dyskinesia; Alginic Sodium Diester injection for ischemic heart, cerebrovascular, and high lipoprotein blood diseases; Bumetanide injection for edema diseases, hypertension, acute renal failure, hyperkalemia, hypercalcemia, and acute drug poisoning; and Candesartan for hypertension. It offers Roxithromycin dispersible tablets for pharyngitis and tonsillitis; Cefaclor dispersible tablets for tympanitis, lower respiratory tract infection, urinary tract infections, and skin/skin tissue infection; Cefalexin capsules for acute tonsillitis; Andrographolide for sore throat caused by upper respiratory tract infection; Clarithromycin granules and capsules; and Naproxen Sodium and Pseudophedrine Hydrochlorida sustained release tablets, as well as Hepatocyte growth-promoting factors, Tiopronin, Compound Ammonium Glycyrrhetate S, and Omeparzole for the treatment of digestive diseases. In addition, the company provides Vitamin B6 injection; Granisetron Hydrochloride injection for nausea and vomiting caused by radiotherapy and chemotherapy during the treatment of malignant tumors; Noni Enzyme, a food supplement; sanitizers; and masks. It supplies its products to hospitals and OTC pharmacies through provincial and municipal pharmaceutical logistics companies. The company is based in Haikou, the People's Republic of China.
đ° Latest News
No news articles available at the moment. Check back later for updates on CPHI.
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Reconciled Cost Of Revenue | $4,276,218 | $6,514,577 | $7,292,384 | $8,598,008 |
| Cost Of Revenue | $4,276,218 | $6,514,577 | $7,292,384 | $8,598,008 |
| Total Revenue | $4,144,268 | $4,528,929 | $7,011,299 | $8,104,092 |
| Operating Revenue | $4,144,268 | $4,528,929 | $7,011,299 | $8,104,092 |
| Expenses | ||||
| Interest Expense | $102,037 | $154,140 | $333,600 | $434,619 |
| Total Expenses | $7,232,808 | $9,112,093 | $9,778,876 | $11,746,920 |
| Other Income Expense | $1,018 | $-5,702 | $15,757 | $93,851 |
| Net Non Operating Interest Income Expense | $-100,034 | $-147,499 | $-326,998 | $-423,864 |
| Interest Expense Non Operating | $102,037 | $154,140 | $333,600 | $434,619 |
| Operating Expense | $2,956,590 | $2,597,516 | $2,486,492 | $3,148,912 |
| Other Operating Expenses | $-151,556 | - | - | - |
| Selling And Marketing Expense | $375,786 | $528,824 | $780,328 | $1,069,785 |
| General And Administrative Expense | $2,451,459 | $1,784,750 | $1,466,084 | $1,893,269 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-3,187,556 | $-4,736,365 | $-3,078,818 | $-3,972,841 |
| Net Interest Income | $-100,034 | $-147,499 | $-326,998 | $-423,864 |
| Interest Income | $2,003 | $6,641 | $6,602 | $10,755 |
| Normalized Income | $-3,188,574 | $-4,730,663 | $-3,094,575 | $-4,066,692 |
| Net Income From Continuing And Discontinued Operation | $-3,187,556 | $-4,736,365 | $-3,078,818 | $-3,972,841 |
| Total Operating Income As Reported | $-3,239,078 | $-4,588,866 | $-2,751,820 | $-3,548,977 |
| Net Income Common Stockholders | $-3,187,556 | $-4,736,365 | $-3,078,818 | $-3,972,841 |
| Net Income | $-3,187,556 | $-4,736,365 | $-3,078,818 | $-3,972,841 |
| Net Income Including Noncontrolling Interests | $-3,187,556 | $-4,736,365 | $-3,078,818 | $-3,972,841 |
| Net Income Continuous Operations | $-3,187,556 | $-4,736,365 | $-3,078,818 | $-3,972,841 |
| Pretax Income | $-3,187,556 | $-4,736,365 | $-3,078,818 | $-3,972,841 |
| Special Income Charges | $1,018 | $-5,702 | $15,757 | $93,851 |
| Interest Income Non Operating | $2,003 | $6,641 | $6,602 | $10,755 |
| Operating Income | $-3,088,540 | $-4,583,164 | $-2,767,577 | $-3,642,828 |
| Gross Profit | $-131,950 | $-1,985,648 | $-281,085 | $-493,916 |
| Per Share | ||||
| Diluted EPS | $-0.74 | $-2.71 | $-9.10 | $-37.80 |
| Basic EPS | $-0.74 | $-2.71 | $-9.10 | $-37.80 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-1,507,368 | $-1,899,526 | $-7,322 | $-931,540 |
| Total Unusual Items | $1,018 | $-5,702 | $15,757 | $93,851 |
| Total Unusual Items Excluding Goodwill | $1,018 | $-5,702 | $15,757 | $93,851 |
| Reconciled Depreciation | $1,579,169 | $2,676,997 | $2,753,653 | $2,700,533 |
| EBITDA (Bullshit earnings) | $-1,506,350 | $-1,905,228 | $8,435 | $-837,689 |
| EBIT | $-3,085,519 | $-4,582,225 | $-2,745,218 | $-3,538,222 |
| Diluted Average Shares | $4,291,427 | $1,746,372 | $338,357 | $105,137 |
| Basic Average Shares | $4,291,427 | $1,746,372 | $338,357 | $105,137 |
| Diluted NI Availto Com Stockholders | $-3,187,556 | $-4,736,365 | $-3,078,818 | $-3,972,841 |
| Tax Provision | $0 | $0 | $0 | $0 |
| Write Off | $-1,018 | $5,702 | $-15,757 | $-93,851 |
| Research And Development | $280,901 | $283,942 | $240,080 | $185,858 |
| Selling General And Administration | $2,827,245 | $2,313,574 | $2,246,412 | $2,963,054 |
| Other Gand A | $2,451,459 | $1,784,750 | $1,466,084 | $1,893,269 |
Fetched: 2026-06-19
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $-1,740,247 | $660,632 | $3,801,705 | $2,078,085 |
| Total Assets | $30,999,464 | $14,887,524 | $16,469,200 | $17,784,143 |
| Total Non Current Assets | $28,653,057 | $11,617,135 | $10,472,267 | $11,819,597 |
| Goodwill And Other Intangible Assets | $24,479,999 | $7,087,272 | $3,652,916 | $2,211,913 |
| Other Intangible Assets | $24,479,999 | $7,087,272 | $3,652,916 | $2,211,913 |
| Current Assets | $2,346,407 | $3,270,389 | $5,996,933 | $5,964,546 |
| Prepaid Assets | $89,199 | $96,288 | $112,271 | $522,334 |
| Inventory | $1,621,423 | $2,266,154 | $3,732,517 | $2,947,787 |
| Receivables | $290,673 | $281,068 | $728,307 | $464,454 |
| Other Receivables | $49,261 | $30,286 | $157,944 | $29,139 |
| Notes Receivable | $0 | $18,642 | $65,915 | $13,784 |
| Accounts Receivable | $241,412 | $232,140 | $504,448 | $421,531 |
| Allowance For Doubtful Accounts Receivable | $-13,023 | $-13,587,182 | $-13,786,074 | $-16,739,527 |
| Gross Accounts Receivable | $254,435 | $13,819,322 | $14,290,522 | $17,161,058 |
| Cash Cash Equivalents And Short Term Investments | $345,112 | $626,879 | $1,423,838 | $2,029,971 |
| Cash And Cash Equivalents | $345,112 | $626,879 | $1,423,838 | $2,029,971 |
| Debt | ||||
| Net Debt | $3,358,903 | $3,079,175 | $3,092,542 | $6,686,784 |
| Total Debt | $3,887,191 | $3,745,377 | $4,634,017 | $8,757,200 |
| Long Term Debt And Capital Lease Obligation | $111,548 | $1,391,130 | $1,451,801 | $0 |
| Current Debt And Capital Lease Obligation | $3,775,643 | $2,354,247 | $3,182,216 | $8,757,200 |
| Current Debt | $3,704,015 | $2,314,924 | $3,104,489 | $8,716,755 |
| Other Current Borrowings | $3,704,015 | $2,314,924 | $3,104,489 | $8,716,755 |
| Long Term Debt | - | $1,391,130 | $1,411,891 | - |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $8,259,712 | $7,139,620 | $9,014,579 | $13,494,145 |
| Total Non Current Liabilities Net Minority Interest | $859,353 | $2,122,332 | $2,193,915 | $754,698 |
| Non Current Deferred Liabilities | $747,805 | $731,202 | $742,114 | $754,698 |
| Non Current Deferred Taxes Liabilities | $747,805 | $731,202 | $742,114 | $754,698 |
| Current Liabilities | $7,400,359 | $5,017,288 | $6,820,664 | $12,739,447 |
| Current Deferred Liabilities | $111,580 | $162,208 | $90,507 | $520,295 |
| Payables And Accrued Expenses | $1,593,630 | $913,327 | $2,292,435 | $3,089,374 |
| Payables | $1,242,987 | $666,168 | $1,993,606 | $2,684,567 |
| Total Tax Payable | $351,904 | $441,062 | $1,027,186 | $1,065,979 |
| Accounts Payable | $891,083 | $225,106 | $966,420 | $667,082 |
| Other Payable | - | - | $1,243,506 | $951,506 |
| Equity | ||||
| Common Stock Equity | $22,739,752 | $7,747,904 | $7,454,621 | $4,289,998 |
| Total Equity Gross Minority Interest | $22,739,752 | $7,747,904 | $7,454,621 | $4,289,998 |
| Stockholders Equity | $22,739,752 | $7,747,904 | $7,454,621 | $4,289,998 |
| Other Equity Interest | $-180,000 | $-180,000 | - | - |
| Gains Losses Not Affecting Retained Earnings | $11,582,646 | $11,319,642 | $11,452,054 | $11,573,065 |
| Other Equity Adjustments | $11,582,646 | $11,319,642 | $11,452,054 | $11,573,065 |
| Retained Earnings | $-47,214,235 | $-44,026,679 | $-39,290,314 | $-36,211,496 |
| Other | ||||
| Ordinary Shares Number | $15,522,002 | $3,261,910 | $1,062,578 | $149,817 |
| Share Issued | $15,522,002 | $3,261,910 | $1,062,578 | $149,817 |
| Tangible Book Value | $-1,740,247 | $660,632 | $3,801,705 | $2,078,085 |
| Invested Capital | $26,443,767 | $11,453,958 | $11,971,001 | $13,006,753 |
| Working Capital | $-5,053,952 | $-1,746,899 | $-823,731 | $-6,774,901 |
| Capital Lease Obligations | $183,176 | $39,323 | $117,637 | $40,445 |
| Total Capitalization | $22,739,752 | $9,139,034 | $8,866,512 | $4,289,998 |
| Additional Paid In Capital | $58,535,819 | $40,631,679 | $35,282,256 | $28,926,931 |
| Capital Stock | $15,522 | $3,262 | $10,625 | $1,498 |
| Common Stock | $15,522 | $3,262 | $10,625 | $1,498 |
| Preferred Stock | $0 | $0 | $0 | $0 |
| Long Term Capital Lease Obligation | $111,548 | $0 | $39,910 | $0 |
| Current Deferred Revenue | $111,580 | $162,208 | $90,507 | $520,295 |
| Current Capital Lease Obligation | $71,628 | $39,323 | $77,727 | $40,445 |
| Pensionand Other Post Retirement Benefit Plans Current | $1,919,506 | $1,587,506 | $1,255,506 | $372,578 |
| Current Accrued Expenses | $350,643 | $247,159 | $298,829 | $404,807 |
| Net PPE | $4,173,058 | $4,529,863 | $6,819,351 | $9,607,684 |
| Accumulated Depreciation | $-33,489,851 | $-32,098,396 | $-30,394,655 | $-28,350,365 |
| Gross PPE | $37,662,909 | $36,628,259 | $37,214,006 | $37,958,049 |
| Other Properties | $181,828 | $38,298 | $116,610 | $39,046 |
| Machinery Furniture Equipment | $28,175,428 | $27,490,916 | $27,862,560 | $28,527,570 |
| Buildings And Improvements | $9,305,653 | $9,099,045 | $9,234,836 | $9,391,433 |
| Properties | $0 | $0 | $0 | $0 |
| Inventories Adjustments Allowances | $-1,145,240 | $-574,071 | $-129,420 | - |
| Finished Goods | $1,465,243 | $1,619,250 | $1,562,725 | $551,000 |
| Work In Process | $457,817 | $340,404 | $413,597 | $557,146 |
| Raw Materials | $843,603 | $880,571 | $1,885,615 | $1,839,641 |
| Line Of Credit | - | - | - | - |
Fetched: 2026-06-19
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $11,010 | $-697,781 | $-711,203 | $-811,509 |
| Operating Activities | ||||
| Operating Cash Flow | $148,261 | $-406,063 | $-699,686 | $-409,545 |
| Cash Flow From Continuing Operating Activities | $148,261 | $-406,063 | $-699,686 | $-409,545 |
| Operating Gains Losses | - | - | $45,385 | - |
| Investing Activities | ||||
| Capital Expenditure | $-137,251 | $-291,718 | $-11,517 | $-401,964 |
| Investing Cash Flow | $-137,251 | $-291,718 | $-11,517 | $-401,964 |
| Cash Flow From Continuing Investing Activities | $-137,251 | $-291,718 | $-11,517 | $-401,964 |
| Financing Activities | ||||
| Financing Cash Flow | $-294,027 | $-33,782 | $73,145 | $-1,770,007 |
| Cash Flow From Continuing Financing Activities | $-294,027 | $-33,782 | $73,145 | $-1,770,007 |
| Net Other Financing Charges | - | - | - | $-223,013 |
| Other | ||||
| Repayment Of Debt | $-1,255,093 | $-553,896 | $-1,490,049 | $-2,140,921 |
| Issuance Of Debt | $961,066 | $520,114 | $1,563,194 | $593,927 |
| Interest Paid Supplemental Data | $74,765 | $86,765 | $92,439 | $141,797 |
| Income Tax Paid Supplemental Data | $0 | $0 | $0 | $0 |
| End Cash Position | $345,112 | $626,879 | $1,423,838 | $2,029,971 |
| Beginning Cash Position | $626,879 | $1,423,838 | $2,029,971 | $4,859,060 |
| Effect Of Exchange Rate Changes | $1,250 | $-65,396 | $31,925 | $-247,573 |
| Changes In Cash | $-283,017 | $-731,563 | $-638,058 | $-2,581,516 |
| Net Issuance Payments Of Debt | $-294,027 | $-33,782 | $73,145 | $-1,546,994 |
| Net Long Term Debt Issuance | $-294,027 | $-33,782 | $73,145 | $-1,546,994 |
| Long Term Debt Payments | $-1,255,093 | $-553,896 | $-1,490,049 | $-2,140,921 |
| Long Term Debt Issuance | $961,066 | $520,114 | $1,563,194 | $593,927 |
| Net Intangibles Purchase And Sale | $-77,927 | $-253,307 | $0 | - |
| Purchase Of Intangibles | $-77,927 | $-253,307 | $0 | - |
| Net PPE Purchase And Sale | $-59,324 | $-38,411 | $-11,517 | $-401,964 |
| Purchase Of PPE | $-59,324 | $-38,411 | $-11,517 | $-401,964 |
| Change In Working Capital | $14,869,921 | $1,194,661 | $-396,175 | $878,344 |
| Change In Other Working Capital | $-53,444 | $73,716 | $-423,261 | $339,659 |
| Change In Payables And Accrued Expense | $1,116,062 | $-302,701 | $569,823 | $504,456 |
| Change In Payable | $1,116,062 | $-302,701 | $569,823 | $504,456 |
| Change In Account Payable | $650,309 | $-733,916 | $312,045 | $-187,734 |
| Change In Prepaid Assets | $9,127 | $14,466 | $412,342 | $-484,681 |
| Change In Inventory | $589,761 | $1,606,888 | $-17,058 | $689,104 |
| Change In Receivables | $13,208,415 | $-197,708 | $-938,021 | $-170,194 |
| Other Non Cash Items | $3,472 | $2,204 | $-15,757 | - |
| Asset Impairment Charge | $-13,116,745 | $456,440 | $-7,974 | $-93,851 |
| Depreciation Amortization Depletion | $1,579,169 | $2,676,997 | $2,753,653 | $2,700,533 |
| Depreciation And Amortization | $1,579,169 | $2,676,997 | $2,753,653 | $2,700,533 |
| Amortization Cash Flow | $851,609 | $447,246 | $223,796 | $36,558 |
| Amortization Of Intangibles | $851,609 | $447,246 | $223,796 | $36,558 |
| Depreciation | $727,560 | $2,229,751 | $2,529,857 | $2,663,975 |
| Net Income From Continuing Operations | $-3,187,556 | $-4,736,365 | $-3,078,818 | $-3,972,841 |
| Gain Loss On Sale Of PPE | - | $0 | $45,385 | $0 |
| Net Short Term Debt Issuance | - | - | $30,572 | $28,962 |
| Short Term Debt Issuance | - | - | $30,572 | $28,962 |
| Stock Based Compensation | - | - | $0 | $78,270 |
| Short Term Debt Payments | - | - | - | $-2,140,921 |
| Change In Other Current Liabilities | - | - | - | - |
Fetched: 2026-06-19